Effective management of HIV and hepatitis C virus (HCV) coinfection warrants special emphasis on interactions between direct acting antivirals (DAAs) and antiretroviral therapy (ART) along with maintenance of treatment compliance. All HIV-HCV coinfected adult patients (2015–2020) were included in this real-life retrospective study. Prevalence of coinfection, proportion of coinfected patients treated, compliance rate, sustained virological response at week 12 (SVR12) after the end of therapy, and adverse events were assessed. Among 4578 HIV patients, 232 (5.1%) had HCV coinfection. Ninety-two (39.7%) were intravenous drug users. One hundred twenty-eight (55.1%) patients presented to the liver clinic. Seventy-six (32.8%) patients [mean age: 36.6 ± 10.4 years; 65 (85.5%) males; mean CD4 count: 396 ± 246 cells/mL] completed DAA therapy, whereas 52 (22.4%) patients defaulted and 75 (32.3%) were lost to follow-up. Sixty-seven (82.2%) patients had chronic hepatitis and 9 (11.8%) had compensated cirrhosis. Median (range) HCV-RNA was 5.9 × 106 IU/mL (2.4 × 105–9.9 × 105). Among 15 (19.5%) treatment experienced patients, 14 were pegylated interferon experienced and one was NS5A-inhibitor experienced. ART regimens comprised a combination of tenofovir (T), lamivudine (L), efavirenz (E), nevirapine (N), and/or zidovudine (Z) at dosage and modifications as applicable [TLE: 63 (82.9%), ZLN:11 (14.5%), and ZLE: 2 (2.6%)]. Overall, 74 (97.4%) out of 76 patients who completed DAA therapy achieved SVR12. Adverse events were minor and well-tolerated. HIV-HCV-coinfected patients demonstrate excellent SVR12 and tolerability with available DAAs, with no major adverse events.
NACO. Policy & Guidelines | National AIDS Control Organization. MoHFW. GoI. 2015. Available from: https://naco.gov.in/documents/policy-guidelines [Last accessed: July17, 2022].
3.
GhanyMG, MorganTR. Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology, 2020; 71(2):686–721; doi: 10.1002/HEP.31060
4.
PlattL, EasterbrookP, GowerE, et al.Prevalence and burden of HCV co-infection in people living with HIV: A global systematic review and meta-analysis. Lancet Infect Dis, 2016; 16(7):797–808; doi: 10.1016/S1473-3099(15)00485-5
5.
De LédinghenV, BarreiroP, FoucherJ, et al.Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy. J Viral Hepat, 2008; 15(6):427–433; doi: 10.1111/j.1365-2893.2007.00962.x
6.
AndreoniM, GiacomettiA, MaidaI, et al.HIV-HCV co-infection: Epidemiology, pathogenesis and therapeutic implications. Eur Rev Med Pharmacol Sci, 2012; 16(11):1473–1483.
7.
ChrysanthidisT, LoliG, MetallidisS, et al.Mechanisms of accelerated liver fibrosis in HIV-HCV coinfection. AIDS Rev, 2017; 19(3):148–155; doi: 10.24875/AIDSRev.M17000004
8.
FiererDS, DieterichDT, FielMI, et al.Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infection. Clin Infect Dis, 2013; 56(7):1038–1043; doi: 10.1093/cid/cis1206
9.
RadwanD, CachayE, Falade-NwuliaO, et al.HCV screening and treatment uptake among patients in HIV care during 2014–2015. J Acquir Immune Defic Syndr, 2019; 80(5):559–567; doi: 10.1097/QAI.0000000000001949
10.
PyneMT, MalloryM, HillyardDR. HCV RNA measurement in samples with diverse genotypes using versions 1 and 2 of the roche COBAS® AmpliPrep/COBAS® TaqMan® HCV test. J Clin Virol, 2015; 65:54–57; doi: 10.1016/J.JCV.2015.02.002
11.
CastéraL, VergniolJ, FoucherJ, et al.Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology, 2005; 128(2):343–350; doi: 10.1053/j.gastro.2004.11.018
12.
Re VLo, KallanMJ, TateJP, et al.Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: A cohort study. Ann Intern Med, 2014; 160(6):369–379; doi: 10.7326/m13-1829
13.
ChenM, WongWW, LawMG, et al.Hepatitis B and C Co-Infection in HIV patients from the TREAT Asia HIV observational database: Analysis of risk factors and survival. PLoS One, 2016; 11(3):1–17; doi: 10.1371/journal.pone.0150512
14.
PirothL, WittkopL, LacombeK, et al.Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients—French ANRS CO13 HEPAVIH cohort. J Hepatol, 2017; 67(1):23–31; doi: 10.1016/j.jhep.2017.02.012
15.
MartinelloM, AminJ, MatthewsGv, et al.Prevalence and disease burden of HCV coinfection in HIV cohorts in the Asia Pacific region: A systematic review and meta-analysis. AIDS Rev, 2016; 18(2):68–80.
16.
MaguraS, RosenblumA, FongC. Factors associated with medication adherence among psychiatric outpatients at substance abuse risk. Open Addict J, 2011; 4(1):58; doi: 10.2174/1874941001104010058
17.
SorensonJL, MascovichA, WallTL, et al.Medication adherence strategies for drug abusers with HIV/AIDS. AIDS Care, 1998; 10(3):297–312; doi: 10.1080/713612419
18.
HinkinCH, BarclayTR, CastellonSA, et al.Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav, 2007; 11(2):185; doi: 10.1007/S10461-006-9152-0
19.
RonceroC, FusterD, Palma-ÁlvarezRF, et al.HIV and HCV infection among opiate-dependent patients and methadone doses: The PROTEUS study. AIDS Care, 2017; 29(12):1551–1556; doi: 10.1080/09540121.2017.1313384
20.
BhattacharyaD, BelperioPS, ShahoumianTA, et al.Effectiveness of all-oral antiviral regimens in 996 human immunodeficiency virus/hepatitis C virus genotype 1-coinfected patients treated in routine practice. Clin Infect Dis, 2017; 64(12):1711–1720; doi: 10.1093/cid/cix111
21.
NaggieS, CooperC, SaagM, et al.Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med, 2015; 373(8):705–713; doi: 10.1056/nejmoa1501315
22.
RockstrohJK, IngilizP, PetersenJ, et al.Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease. Antivir Ther, 2017; 22(3):225–236; doi: 10.3851/IMP3108
23.
MachadoSM, ViganiAG, LeiteAG, et al.Effectiveness of direct-acting antivirals for hepatitis C virus infection in hepatitis C/HIV coinfected individuals: A multicenter study. Medicine, 2020; 99(30):e21270; doi: 10.1097/MD.0000000000021270
24.
WylesD, BraüN, KottililS, et al.Sofosbuvir and velpatasvir for the treatment of hepatitis C virus in patients coinfected with human immunodeficiency virus type 1: An open-label, phase 3 study. Clin Infect Dis, 2017; 65(1):6–12; doi: 10.1093/cid/cix260
25.
SogniP, GilbertC, LacombeK, et al.All-oral direct-acting antiviral regimens in HIV/hepatitis C virus-coinfected patients with cirrhosis are efficient and safe: Real-life results from the prospective ANRS CO13-HEPAVIH cohort. Clin Infect Dis, 2016; 63(6):763–770; doi: 10.1093/cid/ciw379
26.
SikaviC, ChenPH, LeeAD, et al.Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population. Hepatology, 2018; 67(3):847–857; doi: 10.1002/hep.29642
27.
WylesDL, RuanePJ, SulkowskiMS, et al.Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med, 2015; 373(8):714–725; doi: 10.1056/nejmoa1503153
28.
SikaviC, NajarianL, SaabS. Similar sustained virologic response in real-world and clinical trial studies of hepatitis C/human immunodeficiency virus coinfection. Dig Dis Sci, 2018; 63(11):2829–2839; doi: 10.1007/s10620-018-5215-0
29.
PiekarskaA, JabłonowskaE, GarlickiA, et al.Real life results of direct acting antiviral therapy for HCV infection in HIV–HCV-coinfected patients: Epi-Ter2 study. AIDS Care, 2020; 32(6):762–769; doi: 10.1080/09540121.2019.1645808
30.
BonoraS, PuotiM. Use of daclatasvir in HCV/HIV-coinfected patients in a real-life setting. AIDS Rev, 2017; 19(1):24–34.
31.
DhimanRK, GroverGS, PremkumarM, et al.Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting. J Hepatol, 2019; 71(6):1076–1085; doi: 10.1016/j.jhep.2019.07.006
32.
DhimanRK, ConsultantT, GroverGS, et al.EClinicalMedicine outcomes of real-world integrated HCV microelimination for people who inject drugs: An expansion of the Punjab model. EClinicalMedicine, 2021; 41:101148; doi: 10.1016/j.eclinm.2021.101148
33.
VermaN, MishraS, SinghS, et al.Feasibility, outcomes, and safety of telehepatology services during the COVID-19 pandemic. Hepatol Commun, 2021; 0(0):2021; doi: 10.1002/HEP4.1732
